drugset
Drugs / ARD-101
last change May 2026 re-read 2 minutes ago

ARD-101

also known as Denatonium

Small molecule

Developed for
Prader-Willi syndrome · obesity disorder · obesity, hyperphagia, and developmental delay
Investigated by
Aardvark Therapeutics, Inc. · University of California, San Diego · Children's Hospital Colorado · Stanford University

Trials 5 · a red edge is where a trial was stopped

today NCT06828861 · Ph 3 NCT07197034 · Ph 3 NCT05153434 · Ph 2 NCT05215847 · Ph 2 NCT05121441 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT05153434 May 2022 → Sep 2024 Prader-Willi syndrome Aardvark Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT05215847 Mar 2022 → Feb 2023 obesity disorder Aardvark Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT05121441 Nov 2021 → Nov 2022 obesity disorder Aardvark Therapeutics, Inc. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT06828861 Dec 2024 → May 2026 Prader-Willi syndrome Aardvark Therapeutics, Inc. Terminated No outcome recorded
Phase 3 NCT07197034 Jul 2024 → Apr 2026 Prader-Willi syndrome, obesity, hyperphagia, and developmental delay Aardvark Therapeutics, Inc. Terminated No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT02759926 Comparator Aug 2011 → Nov 2015 obesity disorder Universitaire Ziekenhuizen KU Leuven Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as ARD-101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07197034 ↗
4

NCT05121441 ↗

NCT05215847 ↗

NCT05153434 ↗

NCT06828861 ↗
Known as Denatonium ClinicalTrials.gov intervention name — accepted as the source's own label NCT02759926 ↗
Action Activate “ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.” PMID 41833222 ↗ Mar 2026
Modality Small molecule “ARD-101, a small molecule targeting bitter taste receptors (TAS2Rs), in obese subjects with a body mass index (BMI) of 30-45 kg/m2.” NCT05121441 ↗
Route Oral “Twice daily, oral administration” NCT05121441 ↗